GS-9190

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis C InfectionHCV Infection

Phase 2

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

CompletedNCT00743795

Gilead SciencesHCV Infection

Start: 2008-10-31End: 2013-09-30Updated: 2013-11-05

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

CompletedNCT01072695

Gilead SciencesHCV Infection

Start: 2010-02-28End: 2012-01-31Updated: 2012-05-31

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

CompletedNCT01225380

Gilead SciencesChronic Hepatitis C Infection

Start: 2010-10-31End: 2013-09-30Updated: 2014-01-28